Payment overview · 2025
General Payments
$117.90
6 reported records · 3 companies
Healthcare provider profile · identity verified
Daniel J Flaherty, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROCHESTER, NY · NPI 1659339976
Verified facts
What the public records show
CMS Open Payments records show Daniel J Flaherty, DO received $117.90 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 51.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.22 | 51.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.11 | 27.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.57 | 20.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.90 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.22 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 274 |
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 132 |
| Lisinopril | Lisinopril | 419 | 119 |
| Losartan Potassium | Losartan Potassium | 386 | 98 |
| Metformin Hcl | Metformin Hcl | 345 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 89 |
| Omeprazole | Omeprazole | 315 | 97 |
| Alprazolam | Alprazolam | 269 | 52 |
| Gabapentin | Gabapentin | 268 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 74 |
| Tramadol Hcl | Tramadol Hcl | 248 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 236 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 60 |
| Meloxicam | Meloxicam | 181 | 56 |
| Carvedilol | Carvedilol | 180 | 47 |
| Famotidine | Famotidine | 180 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 55 |
| Trazodone Hcl | Trazodone Hcl | 172 | 42 |
| Sertraline Hcl | Sertraline Hcl | 167 | 45 |
| Simvastatin | Simvastatin | 163 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 51 |
| Eliquis | Apixaban | 146 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 50 |
| Baclofen | Baclofen | 130 | 32 |
| Furosemide | Furosemide | 130 | 43 |
| Glimepiride | Glimepiride | 125 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 24 |
| Methylprednisolone | Methylprednisolone | 112 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | 15 |
| Cephalexin | Cephalexin | 98 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 31 |
| Mirtazapine | Mirtazapine | 95 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 25 |
| Allopurinol | Allopurinol | 88 | 26 |
| Atenolol | Atenolol | 88 | 24 |
| Lorazepam | Lorazepam | 87 | 19 |
| Chlorthalidone | Chlorthalidone | 84 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Ozempic | Semaglutide | 81 | 18 |
| Diazepam | Diazepam | 80 | 15 |
| Potassium Chloride | Potassium Chloride | 80 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 15 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Bupropion Xl | Bupropion Hcl | 69 | 16 |
| Jardiance | Empagliflozin | 69 | 20 |
| Prednisone | Prednisone | 69 | 52 |
| Montelukast Sodium | Montelukast Sodium | 67 | 21 |
| Xarelto | Rivaroxaban | 64 | 11 |
| Clonazepam | Clonazepam | 63 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 14 |
| Torsemide | Torsemide | 55 | 16 |
| Celecoxib | Celecoxib | 53 | 15 |
| Cefdinir | Cefdinir | 51 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 18 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Ibuprofen | Ibuprofen | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Lansoprazole | Lansoprazole | 45 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 35 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 28 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 33 | 13 |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Felodipine Er | Felodipine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Dofetilide | Dofetilide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.90 · 6 records | Novo Nordisk Inc | OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error